{
    "id": 6656,
    "fullName": "MYD88 L265P",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MYD88 L265P (corresponds to L252P in the canonical isoform in UniProt.org) lies within the TIR domain of the Myd88 protein (UniProt.org). L265P confers a gain of function to Myd88, resulting in increased NF-kappaB signaling, and promotes cell survival in culture (PMID: 23836557, PMID: 21179087).",
            "references": [
                {
                    "id": 2808,
                    "pubMedId": 23836557,
                    "title": "A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836557"
                },
                {
                    "id": 2809,
                    "pubMedId": 21179087,
                    "title": "Oncogenically active MYD88 mutations in human lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21179087"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4615,
        "geneSymbol": "MYD88",
        "terms": [
            "MYD88",
            "MYD88D"
        ]
    },
    "variant": "L265P",
    "createDate": "05/26/2015",
    "updateDate": "08/08/2018",
    "referenceTranscriptCoordinates": {
        "id": 152156,
        "transcript": "NM_002468",
        "gDna": "chr3:g.38141150T>C",
        "cDna": "c.794T>C",
        "protein": "p.L265P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3704,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-Hodgkin lymphoma (NHL) patient derived xenograft (PDX) model harboring both CD79B Y197N and MYD88 L265P demonstrated sensitivity to Ibruvica (ibrutinib) while an NHL patient derived xenograft (PDX) model harboring only MYD88 L265P did not respond to Ibruvica (ibrutinib) (ASH 57th Annual Meeting, 2015, abstract #2759).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4013,
                    "pubMedId": null,
                    "title": "Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts",
                    "url": "https://ash.confex.com/ash/2015/webprogram/Paper81154.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12253,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, all of diffuse large B-cell lymphoma patients harboring MYD88 L265P (n=4) did not respond to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10215,
                    "pubMedId": null,
                    "title": "The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study",
                    "url": "http://www.bloodjournal.org/content/120/21/686?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6344,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5531,
                    "pubMedId": 24903481,
                    "title": "MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24903481"
                },
                {
                    "id": 5532,
                    "pubMedId": 25055137,
                    "title": "High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25055137"
                },
                {
                    "id": 5533,
                    "pubMedId": 26792260,
                    "title": "MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26792260"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2469,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMO-8400 resulted in decreased survival of B-cell lymphoma cell lines harboring MYD88 L265P in culture, and decreased tumor growth in a MYD88 L265P-positive B-cell lymphoma cell line xenograft models (Cancer Res October 1, 2014 74:2570).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 2866,
                "therapyName": "IMO-8400",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3125,
                    "pubMedId": null,
                    "title": "Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12106,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two patients with primary central nervous system lymphoma each harboring MYD88 L265P demonstrated a complete response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8322,
                    "pubMedId": 27733371,
                    "title": "TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27733371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13546,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYD88 L265P is diagnostic and aids distinguishing Waldenstrom macroglobulinemia from IgM-secreting B-cell lymphomas and IgM plasma cell myeloma (NCCN.org).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2623,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* demonstrated resistance to Imbruvica (Ibrutinib) in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2629,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2626,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-treatment with Mozobil (plerixafor) overcame resistance to Imbruvica (Ibrutinib) in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2627,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-treatment with Mozobil (plerixafor) overcame resistance to Imbruvica (Ibrutinib) in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S344fs in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9807,
                "profileName": "CXCR4 S344fs MYD88 L265P"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S344fs demonstrated resistance to Imbruvica (Ibrutinib) in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9807,
                "profileName": "CXCR4 S344fs MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2630,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S344fs in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9807,
                "profileName": "CXCR4 S344fs MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2625,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 T311fs demonstrated resistance to Imbruvica (Ibrutinib) in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9808,
                "profileName": "CXCR4 T311fs MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2631,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 T311fs in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9808,
                "profileName": "CXCR4 T311fs MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2628,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-treatment with Mozobil (plerixafor) overcame resistance to Imbruvica (Ibrutinib) in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 T311fs in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9808,
                "profileName": "CXCR4 T311fs MYD88 L265P"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13547,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstr\u00f6m's macroglobulinemia, with the best response seen in patients harboring the MYD88 L265P and wild-type CXCR4 genotype (100%, 91.2%, 35 patients), followed by MYD88 L265P and mutant CXCR4 (85.7%, 61.9%, 21 patients), then wild-type MYD88 and CXCR4 (71.4%, 28.6%, 7 patients) (PMID: 25853747; NCT01614821).",
            "molecularProfile": {
                "id": 9814,
                "profileName": "CXCR4 wild-type MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2810,
                    "pubMedId": 25853747,
                    "title": "Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25853747"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2632,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing wild-type CXCR4 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9814,
                "profileName": "CXCR4 wild-type MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3703,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-Hodgkin lymphoma (NHL) patient derived xenograft (PDX) model co-harboring CD79B Y197N and MYD88 L265P demonstrated sensitivity to Ibruvica (ibrutinib) while an NHL patient derived xenograft (PDX) model harboring only MYD88 L265P did not respond to Ibruvica (ibrutinib) (ASH 57th Annual Meeting, 2015, abstract #2759).",
            "molecularProfile": {
                "id": 14907,
                "profileName": "CD79B Y197N MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4013,
                    "pubMedId": null,
                    "title": "Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts",
                    "url": "https://ash.confex.com/ash/2015/webprogram/Paper81154.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11550,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with Waldenstr\u00f6m macroglobulinemia, a form of non-Hodgkin lymphoma, harboring BTK C481R, BTK C481S, CXCR4 mutant, and MYD88 L265P, demonstrated resistance to treatment with Imbruvica (ibrutinib) (PMID: 28235842).",
            "molecularProfile": {
                "id": 28134,
                "profileName": "BTK C481R BTK C481S CXCR4 mut MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9635,
                    "pubMedId": 28235842,
                    "title": "Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28235842"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11551,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with Waldenstr\u00f6m macroglobulinemia, a form of non-Hodgkin lymphoma, harboring BTK C481R, BTK C481S, CARD11 L878F, and MYD88 L265P, demonstrated resistance to treatment with Imbruvica (ibrutinib) (PMID: 28235842).",
            "molecularProfile": {
                "id": 28138,
                "profileName": "BTK C481R BTK C481S CARD11 L878F MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9635,
                    "pubMedId": 28235842,
                    "title": "Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28235842"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12107,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring both CD79B Y196H and MYD88 L265P demonstrated a partial response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28411,
                "profileName": "CD79B Y196H MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12108,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring CD79B Y196D, MYD88 L265P, and TNFAIP3 L324Qfs*7 demonstrated a partial response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28412,
                "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 L324Qfs*7"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12109,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring CD79B Y196D, MYD88 L265P, and TNFAIP3 del demonstrated a partial response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28414,
                "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 del"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12111,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring both CD79B Y196S and MYD88 L265P demonstrated stable disease when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28416,
                "profileName": "CD79B Y196S MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12254,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, all the diffuse large B-cell lymphoma patients harboring both MYD88 L265P and CD79B mutations (n=4) responded to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686).",
            "molecularProfile": {
                "id": 28604,
                "profileName": "CD79B mut MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10215,
                    "pubMedId": null,
                    "title": "The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study",
                    "url": "http://www.bloodjournal.org/content/120/21/686?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13548,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstr\u00f6m's macroglobulinemia, with the best response seen in patients harboring the MYD88 L265P and wild-type CXCR4 genotype (100%, 91.2%, 35 patients), followed by MYD88 L265P and mutant CXCR4 (85.7%, 61.9%, 21 patients), then wild-type MYD88 and CXCR4 (71.4%, 28.6%, 7 patients) (PMID: 25853747; NCT01614821).",
            "molecularProfile": {
                "id": 29152,
                "profileName": "CXCR4 mut MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2810,
                    "pubMedId": 25853747,
                    "title": "Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25853747"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6507,
            "profileName": "MYD88 L265P",
            "profileTreatmentApproaches": [
                {
                    "id": 5837,
                    "name": "IMO-8400",
                    "profileName": "MYD88 L265P"
                },
                {
                    "id": 4938,
                    "name": "Ibrutinib",
                    "profileName": "MYD88 L265P"
                }
            ]
        },
        {
            "id": 9806,
            "profileName": "CXCR4 S338* MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9807,
            "profileName": "CXCR4 S344fs MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9808,
            "profileName": "CXCR4 T311fs MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9814,
            "profileName": "CXCR4 wild-type MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14907,
            "profileName": "CD79B Y197N MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28134,
            "profileName": "BTK C481R BTK C481S CXCR4 mut MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28138,
            "profileName": "BTK C481R BTK C481S CARD11 L878F MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28411,
            "profileName": "CD79B Y196H MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28412,
            "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 L324Qfs*7",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28414,
            "profileName": "CD79B Y196D MYD88 L265P TNFAIP3 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28416,
            "profileName": "CD79B Y196S MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28604,
            "profileName": "CD79B mut MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29152,
            "profileName": "CXCR4 mut MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 152156,
            "transcript": "NM_002468",
            "gDna": "chr3:g.38141150T>C",
            "cDna": "c.794T>C",
            "protein": "p.L265P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}